Leonardo Sahelijo

First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals

Yi Wang, Richard Larouche, Zhao-Xue Yu, 2015 .

Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy

David A. Katz, A. Bhathena, Anahita Bhathena, 2008, Nature Reviews Drug Discovery.